Anti-S IgG Seroresponses changed from baseline at 168 days after vaccination;Anti-S IgG Seroresponses changed from baseline at 28 days after vaccination;Anti-S IgG Seroresponses changed from baseline at 336 days after vaccination;Anti-S IgG Seroresponses changed from baseline at 84 days after vaccination;Frequency of all unsolicited AEs;Frequency of solicited reportable local adverse event after vaccination;Frequency of solicited reportable systemic adverse event after vaccination;GMFR changed from baseline in anti-S IgG GMT at 168 days after vaccination;GMFR changed from baseline in anti-S IgG GMT at 28 days after vaccination;GMFR changed from baseline in anti-S IgG GMT at 336 days after vaccination;GMFR changed from baseline in anti-S IgG GMT at 84 days after vaccination;GMT Anti-S IgG at 14 days after vaccination in subject subjects;GMT Anti-S IgG at 168 days after vaccination;GMT Anti-S IgG at 28 days after vaccination;GMT Anti-S IgG at 336 days after vaccination;GMT Anti-S IgG at 7 days after vaccination in subset subjects;GMT Anti-S IgG at 84 days after vaccination;GMT Anti-S IgG at baseline

Anti-S IgG Seroresponses changed from baseline at 168 days after vaccination;Anti-S IgG Seroresponses changed from baseline at 28 days after vaccination;Anti-S IgG Seroresponses changed from baseline at 336 days after vaccination;Anti-S IgG Seroresponses changed from baseline at 84 days after vaccination;Frequency of all unsolicited AEs;Frequency of solicited reportable local adverse event after vaccination;Frequency of solicited reportable systemic adverse event after vaccination;GMFR changed from baseline in anti-S IgG GMT at 168 days after vaccination;GMFR changed from baseline in anti-S IgG GMT at 28 days after vaccination;GMFR changed from baseline in anti-S IgG GMT at 336 days after vaccination;GMFR changed from baseline in anti-S IgG GMT at 84 days after vaccination;GMT Anti-S IgG at 14 days after vaccination in subject subjects;GMT Anti-S IgG at 168 days after vaccination;GMT Anti-S IgG at 28 days after vaccination;GMT Anti-S IgG at 336 days after vaccination;GMT Anti-S IgG at 7 days after vaccination in subset subjects;GMT Anti-S IgG at 84 days after vaccination;GMT Anti-S IgG at baseline

the IgG immune response against the Spike protein of SARS-CoV-2;the safety and reactogenicity of Ad26.COV2.S as a heterologous vaccination

the IgG immune response against the Spike protein of SARS-CoV-2;the safety and reactogenicity of Ad26.COV2.S as a heterologous vaccination